Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -44.81% is in line with its 5-year average of -44.10%, around the middle of its 5-year range (-72.17%–-21.38%).
As of the fiscal period ended Tuesday, June 30, 2026. 22.42% above its 12-month average of -57.76%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -44.81%.
RETURN ON INVESTED CAPITAL (ROIC)
-44.81%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-57.76%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-48.21%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-44.10%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+22.42%
CURRENT VS 3Y AVG
+7.06%
CURRENT VS 5Y AVG
-1.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.80%
median of 696 covered companies
CURRENT VS SECTOR MEDIAN
-32.57%
vs the sector median at left
Foghorn Therapeutics Inc.
Market Cap
$116.06M
Return on Invested Capital (ROIC)
-44.81%
TTM Avg
-57.76%
3Y Avg
-48.21%
5Y Avg
-44.10%
Market Cap
$116.80M
Return on Invested Capital (ROIC)
-192.18%
TTM Avg
-186.03%
3Y Avg
-161.77%
5Y Avg
-220.86%
Market Cap
$117.03M
Return on Invested Capital (ROIC)
-87.72%
TTM Avg
-74.88%
3Y Avg
-52.32%
5Y Avg
-62.32%
Market Cap
$117.05M
Return on Invested Capital (ROIC)
-0.05%
TTM Avg
-44.27%
3Y Avg
-81.25%
5Y Avg
-78.53%
Market Cap
$115.04M
Return on Invested Capital (ROIC)
-145.10%
TTM Avg
-158.49%
3Y Avg
-239.94%
5Y Avg
-201.97%
Market Cap
$114.31M
Return on Invested Capital (ROIC)
-223.06%
TTM Avg
-221.51%
3Y Avg
-125.15%
5Y Avg
-99.68%
Market Cap
$114.08M
Return on Invested Capital (ROIC)
-19.83%
TTM Avg
-23.34%
3Y Avg
-19.01%
5Y Avg
-18.39%
Market Cap
$118.88M
Return on Invested Capital (ROIC)
-61.84%
TTM Avg
-30.30%
3Y Avg
-57.06%
5Y Avg
-116.42%
Market Cap
$111.61M
Return on Invested Capital (ROIC)
-97.99%
TTM Avg
-45.11%
3Y Avg
-60.38%
5Y Avg
-60.38%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $116.06M | -44.81% | -57.76% | -48.21% | -44.10% |
| Genelux Corporation (GNLX)vs › | $116.80M | -192.18% | -186.03% | -161.77% | -220.86% |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | -87.72% | -74.88% | -52.32% | -62.32% |
| Coya Therapeutics, Inc. (COYA)vs › | $117.05M | -0.05% | -44.27% | -81.25% | -78.53% |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.04M | -145.10% | -158.49% | -239.94% | -201.97% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $114.31M | -223.06% | -221.51% | -125.15% | -99.68% |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | -19.83% | -23.34% | -19.01% | -18.39% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.88M | -61.84% | -30.30% | -57.06% | -116.42% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.61M | -97.99% | -45.11% | -60.38% | -60.38% |
| BGM Group Ltd. (BGM)vs › | $111.27M | -3.19% | -2.23% | -1.75% | 1.24% |
ROIC
-44.8%
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -44.81% |
| 2026-03-31 | -50.60% |
| 2025-12-31 | -59.34% |
| 2025-09-30 | -72.17% |
| 2025-06-30 | -61.88% |
| 2025-03-31 | -51.98% |
| 2024-12-31 | -47.32% |
| 2024-09-30 | -41.40% |
| 2024-06-30 | -35.06% |
| 2024-03-31 | -50.65% |
| 2023-12-31 | -47.44% |
| 2023-09-30 | -43.74% |
| 2023-06-30 | -44.36% |
| 2023-03-31 | -38.68% |
| 2022-12-31 | -33.50% |
| 2022-09-30 | -29.93% |
| 2022-06-30 | -27.23% |
| 2022-03-31 | -23.95% |
| 2021-12-31 | -21.38% |
| 2021-09-30 | -56.02% |
| 2021-06-30 | -44.59% |
| 2021-03-31 | -36.50% |
| 2020-12-31 | -28.95% |
| 2020-09-30 | -49.51% |
| 2020-06-30 | -68.97% |
| 2019-12-31 | -369.05% |
